Roy Herbst, MD, PhD, from the Yale Cancer Center and Yale School of Medicine, presented a groundbreaking abstract at the…
Browsing: Non-small Cell Lung Cancer
Non-Small Cell Lung Cancer (NSCLC) is a complex and aggressive form of lung cancer, but developments in treatments and therapies…
Ticiana Leal, MD, from the Winship Cancer Institute of Emory University, has conducted a randomized, phase 3 study called LUNAR,…
Pembrolizumab’s approval in this setting does not mean clinical value for Adjuvant Therapy for Resected NSCLC By Jack West, MD…
iFrame is not supported! Pembrolizumab’s approval in this setting does not mean clinical value for Adjuvant Therapy for Resected NSCLC…
Pembrolizumab’s approval in this setting does not mean clinical value for Adjuvant Therapy for Resected NSCLC By Jack West, MD…
KRAS Lung Cancer: Taking on Goliath Discussion by Jai Luo MD By Jai Luo, MD Hi there, my name is…
CEACAM5: Safety and Efficacy Outcome in Long-term Treatment with SAR408701 in Pts with NSQ NSCLC Prof Charles Ricordel By Professor…
Plinabulin Improved OS and lower Toxicity in NSCLC EGFR Wild Type The DUBLIN-3 was a randomized phase III trial from…
Single agent VS-6766 or VS-6766 plus defactinib in KRAS-mutant non-small-cell lung cancer: the RAMP-202 phase II trial 5 Key Conclusions:…